CD274 and thyroid gland carcinoma: Currently, several phase II clinical trials targeting the PD-1-PD-L1 axis are underway in thyroid cancer, for example, a human phase II study demonstrated that Spartalizumab (PDR001 is a humanized immunoglobulin 4 monoclonal antibody), which binds to PD-1 and blocks the interaction between PD-1 and PD-L1 and PD-L2, showed promising results in advanced and metastatic ATC patients, demonstrating favorable clinical activity and a favorable safety profile (165).